Fintel reports that on October 31, 2025, Evercore ISI Group maintained coverage of Janus Henderson Group (NYSE:JHG) with a In ...

Q3 2025 Earnings Call October 30, 2025 9:00 AM EDTCompany ParticipantsAli Dibadj - CEO & DirectorRoger Thompson - ...

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The ...

Janus Henderson Group (JHG) delivered earnings and revenue surprises of +7.92% and -0.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the ...

While the top- and bottom-line numbers for Janus Henderson Group (JHG) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key ...

Relmada Therapeutics ( ($RLMD) ) has shared an announcement. On November 4, 2025, Relmada Therapeutics announced the pricing of a $100 million ...

Return on Assets (ROA): Affiliated Managers Group's ROA falls below industry averages, indicating challenges in efficiently ...

Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today ...

Nvidia is poised to benefit from robust AI infrastructure spending, with demand likely strong through at least 2027. Learn ...

The energy industry is known for its strong commitment to shareholders and generous payouts. According to figures from Janus Henderson, the oil, gas, and energy sector reported an annual underlying ...

Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% ...

Janus Henderson Group has an analyst consensus of Moderate Buy, with a price target consensus of $50.14, implying a 16.58% upside from current levels. In a report released on October 28, TR | OpenAI – ...